2023.10.10
球盟会官网入口基因基因治疗研发副总裁
Cure Genetics is delighted to announce that Dr. Pengcheng Zhou has joined the company on August 21, 2023, taking on the role of Vice President of Gene Therapy Research and Development, responsible for the research and translation of the company's gene therapy products. Dr. Zhou brings with him decades of extensive experience in the AAV gene therapy domain, showcasing remarkable achievements at leading academic institutions and renowned companies including Harvard University, Voyager, Luye Pharma, and Frontera Therapeutics.
Prior to joining Cure Genetics, Dr. Zhou served as the head of Preclinical Development and Bioanalytical Sciences at Frontera Therapeutics. There, he led the preclinical research and development of AAV gene therapies targeting a range of indications from ocular to neurodegenerative to cardiac diseases and successfully spearheaded the IND applications and approvals for several Frontera's projects. Before Frontera, Dr. Zhou served at Luye Pharmaceuticals, establishing and leading the development of AAV gene therapies for ophthalmology, the central nervous system, hematology, and metabolic indications.
Dr. Zhou was also a founding scientist at Voyager Therapeutics. He deeply participated in the construction and growth of Voyager and made significant contributions, including establishing research laboratories, animal facilities, preclinical R&D teams, and various technical/scientific platforms and R&D pipelines. At Voyager, Dr. Zhou led and completed all preclinical research and development for the gene therapy VY-HTT01 for Huntington's disease (HD), successfully submitting the VT-HTT01 IND and receiving FDA approval. Moreover, during his six-year tenure at Voyager, Dr. Zhou led multiple core research platforms to support the development of all Voyager projects.
Before his tenure in the industrial sector, Dr. Zhou was an instructor at Harvard Medical School, focusing on the research of the role of growth factors in human diseases. His research outcomes have been published in renowned journals such as Neuron, Developmental Cell, PNAS, and JBC. Dr. Zhou obtained his Ph.D. from Peking University and underwent postdoctoral training at Harvard Medical School. He is an honorary member of both the American Society of Gene & Cell Therapy and the Society for Neuroscience.
Dr. Zhou stated, "Cure Genetics has a profound accumulation in the field of gene therapy, and its differentiated AAV directed evolution platform VELPTM also has distinct advantages. I look forward to collaborating with the team to accelerate the research and translation of the company's gene therapy products and extend its application to a broader range of diseases targeting nervous system, heart, kidneys etc."
"We are very much looking forward to Dr. Zhou joining Cure Genetics. Dr. Zhou is an outstanding basic and translational research scientist. His rich experience in the gene therapy field will undoubtedly further propel the accelerated development of the company's gene therapy platform and differentiated pipelines. This will have a profound impact on advancing the company's strategy, laying a solid foundation for the company's future development. " said Dr. Yuanyuan Xu, Chairman & CEO of Cure Genetics.
Cure Genetics, established in Suzhou in 2016, is a clinical-stage company dedicated to developing cell and gene therapies for solid tumors and common genetic diseases. Through our innovative AIMS CAR-NKT and VELPTM AAV platform , Cure Genetics has developed a differentiated pipeline. By leveraging global collaborations and out-license, we actively drive the research & development, and commercialization of innovative drugs. We aim to provide effective treatment measures for patients worldwide with unmet medical needs and to become a benchmark in the global field of cell and gene therapy.
